LMR Partners’s Neurocrine Biosciences NBIX Stock Holding History

LMR Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.36M	Hold	55,545	–	–	0.03%	444
2026 Q1	$7.32M	Buy	+55,545	New	+$7.37M	0.02%	524
2024 Q4	–	Sell	-47,740	Closed	-$5.5M	–	1470
2024 Q3	$5.5M	Buy	+47,740	New	+$6.54M	0.04%	347
2024 Q1	–	Sell	-2,905	Closed	-$397K	–	1259
2023 Q4	$383K	Hold	2,905	–	–	﹤0.01%	678
2023 Q3	$327K	Hold	2,905	–	–	﹤0.01%	595
2023 Q2	$274K	Hold	2,905	–	–	﹤0.01%	560
2023 Q1	$294K	Hold	2,905	–	–	﹤0.01%	803
2022 Q4	$347K	Sell	2,905 -2,095	-42%	-$245K	0.01%	931
2022 Q3	$531K	Buy	+5,000	New	+$507K	0.01%	855
2019 Q4	–	Sell	-46,767	Closed	-$4.21M	–	500
2019 Q3	$4.21M	Buy	46,767 +34,062	+268%	+$3.18M	0.21%	73
2019 Q2	$1.07M	Buy	+12,705	New	+$1.04M	0.04%	224
2018 Q4	–	Sell	-82,430	Closed	-$10.1M	–	434
2018 Q3	$10.1M	Buy	+82,430	New	+$9.35M	0.64%	43
2016 Q3	–	Sell	-57,800	Closed	-$2.63M	–	434
2016 Q2	$2.63M	Buy	+57,800	New	+$2.66M	0.41%	70

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

LMR Partners's NBIX Position: Q2 2026 in Review

LMR Partners held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 55,545 shares worth $9.36M. The position accounts for 0.03% of the portfolio, ranked #444.

LMR Partners first reported a position in NBIX in Q2 2016 and has held it in 13 quarters since. The position peaked at $10.1M in Q3 2018. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

LMR Partners held 55,545 shares of Neurocrine Biosciences worth $9.36M as of Q2 2026.
LMR Partners left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up 0.03% of LMR Partners's portfolio in Q2 2026, its #444 holding.
LMR Partners first reported a position in Neurocrine Biosciences in Q2 2016 and has held it in 13 quarters since.
LMR Partners's Neurocrine Biosciences position peaked at $10.1M in Q3 2018.
777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.